Thomas Schwarzmayr
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Thomas Schwarzmayr has a total of 111 co-authors. Here are the top co-authors by number of shared publications:
- Tim-Matthias Strom
Institute of Human Genetics, Helmholtz Zentrum München, Neuherberg, Germany
5 shared publications - Elisabeth Graf
Institute of Human Genetics, School of Medicine and Health, Technical University of Munich Munich Germany
3 shared publications - Davide Calebiro
University of Birmingham
2 shared publications - Felix Beuschlein
Department of Endocrinology, Diabetology and Clinical Nutrition, University Hospital Zurich and University of Zurich, Zurich, Switzerland
2 shared publications - Kerstin Bathon
Institute of Pharmacology and Toxicology and Bio-Imaging Center/Rudolf Virchow Center, University of Würzburg, Würzburg, Germany
2 shared publications - Martin Reincke
Medizinische Klinik und Poliklinik IV, Endocrine Research Unit, Klinikum der Universität München, LMU, Munich, Germany
2 shared publications
Latest Publications
- Open Access
Adaptive mitochondrial regulation of the proteasome
Summary: The proteasome is the main proteolytic system for targeted protein degradation in the cell. Its function is fine-tuned according to cellular needs. Regulation of proteasome function by mitochondrial metabolism, however, is unknown. Here, we demonstrate that mitochondrial dysfunction reduces the assembly and activity of the 26S proteasome in the absence of oxidative stress. Impaired respiratory complex I function leads to metabolic reprogramming of the Krebs cycle and deficiency in aspartate. Aspartate supplementation activates assembly and activity of 26S proteasomes via transcriptional activation of the proteasome assembly factors p28 and Rpn6. This metabolic adaptation of 26S proteasome function involves sensing of aspartate via the mTORC1 pathway. Metformin treatment of primary human cells similarly reduced assembly and activity of 26S proteasome complexes, which was fully reversible and rescued by supplementation of aspartate or pyruvate. Of note, respiratory dysfunction conferred resistance towards the proteasome inhibitor Bortezomib. Our study uncovers a fundamental novel mechanism of how mitochondrial metabolism adaptively adjusts protein degradation by the proteasome. It thus unravels unexpected consequences of defective mitochondrial metabolism in disease or drug-targeted mitochondrial reprogramming for proteasomal protein degradation in the cell. As metabolic inhibition of proteasome function can be alleviated by treatment with aspartate or pyruvate, our results also have therapeutic implications.
Open AccessAdaptive mitochondrial regulation of the proteasome
Summary: The proteasome is the main proteolytic system for targeted protein degradation in the cell. Its function is fine-tuned according to cellular needs. Regulation of proteasome function by mitochondrial metabolism, however, is unknown. Here, we demonstrate that mitochondrial dysfunction reduces the assembly and activity of the 26S proteasome in the absence of oxidative stress. Impaired respiratory complex I function leads to metabolic reprogramming of the Krebs cycle and deficiency in aspartate. Aspartate supplementation activates assembly and activity of 26S proteasomes via transcriptional activation of the proteasome assembly factors p28 and Rpn6. This metabolic adaptation of 26S proteasome function involves sensing of aspartate via the mTORC1 pathway. Metformin treatment of primary human cells similarly reduced assembly and activity of 26S proteasome complexes, which was fully reversible and rescued by supplementation of aspartate or pyruvate. Of note, respiratory dysfunction conferred resistance towards the proteasome inhibitor Bortezomib. Our study uncovers a fundamental novel mechanism of how mitochondrial metabolism adaptively adjusts protein degradation by the proteasome. It thus unravels unexpected consequences of defective mitochondrial metabolism in disease or drug-targeted mitochondrial reprogramming for proteasomal protein degradation in the cell. As metabolic inhibition of proteasome function can be alleviated by treatment with aspartate or pyruvate, our results also have therapeutic implications.
- Open Access
Maintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer
Despite important advances in the treatment of breast cancer, the 5-year survival rate for patients with distant metastasis remains less than 30%. Metastasis is a complex, multi-step process beginning with local invasion and ending with the outgrowth of systemically disseminated cells into actively proliferating metastases that ultimately cause the destruction of vital organs. It is this last step that limits patient survival and, at the same time, remains the least understood mechanistically. Here, we focus on understanding determinants of metastatic outgrowth using metastatic effusion biopsies from stage IV breast cancer patients. By modelling metastatic outgrowth through xenograft transplantation, we show that tumour initiation potential of patient-derived metastatic breast cancer cells across breast cancer subtypes is strongly linked to high levels of EPCAM expression. Breast cancer cells with high EPCAM levels are highly plastic and, upon induction of epithelial-mesenchymal transition (EMT), readily adopt mesenchymal traits while maintaining epithelial identity. In contrast, low EPCAM levels are caused by the irreversible reprogramming to a mesenchymal state with concomitant suppression of metastatic outgrowth. The ability of breast cancer cells to retain epithelial traits is tied to a global epigenetic program that limits the actions of EMT-transcription factor ZEB1, a suppressor of epithelial genes. Our results provide direct evidence that maintenance of epithelial identity is required for metastatic outgrowth while concomitant expression of mesenchymal markers enables plasticity. In contrast, loss of epithelial traits is characteristic of an irreversible mesenchymal reprogramming associated to a deficiency for metastatic outgrowth. Collectively, our data provide a framework for the intricate intercalation of mesenchymal and epithelial traits in metastatic growth.
Open AccessMaintenance of epithelial traits and resistance to mesenchymal reprogramming promote proliferation in metastatic breast cancer
Despite important advances in the treatment of breast cancer, the 5-year survival rate for patients with distant metastasis remains less than 30%. Metastasis is a complex, multi-step process beginning with local invasion and ending with the outgrowth of systemically disseminated cells into actively proliferating metastases that ultimately cause the destruction of vital organs. It is this last step that limits patient survival and, at the same time, remains the least understood mechanistically. Here, we focus on understanding determinants of metastatic outgrowth using metastatic effusion biopsies from stage IV breast cancer patients. By modelling metastatic outgrowth through xenograft transplantation, we show that tumour initiation potential of patient-derived metastatic breast cancer cells across breast cancer subtypes is strongly linked to high levels of EPCAM expression. Breast cancer cells with high EPCAM levels are highly plastic and, upon induction of epithelial-mesenchymal transition (EMT), readily adopt mesenchymal traits while maintaining epithelial identity. In contrast, low EPCAM levels are caused by the irreversible reprogramming to a mesenchymal state with concomitant suppression of metastatic outgrowth. The ability of breast cancer cells to retain epithelial traits is tied to a global epigenetic program that limits the actions of EMT-transcription factor ZEB1, a suppressor of epithelial genes. Our results provide direct evidence that maintenance of epithelial identity is required for metastatic outgrowth while concomitant expression of mesenchymal markers enables plasticity. In contrast, loss of epithelial traits is characteristic of an irreversible mesenchymal reprogramming associated to a deficiency for metastatic outgrowth. Collectively, our data provide a framework for the intricate intercalation of mesenchymal and epithelial traits in metastatic growth.
- Open Access
Epstein-Barr virus reprograms human B-lymphocytes immediately in the pre-latent phase of infection
Epstein-Barr virus (EBV) is a human tumor virus and a model of herpesviral latency. The virus efficiently infects resting human B-lymphocytes and induces their continuous proliferation in vitro, which mimics certain aspects of EBV’s oncogenic potential in vivo. This seminal finding was made 50 years ago, but how EBV activates primary human B-lymphocytes and how lymphoblastoid cell lines (LCLs) evolve from the EBV-infected lymphocytes is uncertain. We conducted a systematic time-resolved longitudinal study of cellular functions and transcriptional profiles of newly infected naïve primary B-lymphocytes. EBV reprograms these human cells comprehensively and globally. Rapid and extensive transcriptional changes occur within 24 hours of infection and precede any metabolic and phenotypic changes. Within the next 48 hours, the virus activates the cells, changes their phenotypes with respect to cell size, RNA and protein content and induces metabolic pathways to cope with the increased demand for energy, supporting an efficient cell cycle entry on day three post infection. The transcriptional program that EBV initiates consists of three waves of clearly discernable clusters of cellular genes that peak on day one, two, or three and regulate RNA synthesis, metabolic pathways and cell division, respectively. Upon the onset of cell doublings on day four the cellular transcriptome appears to be completely reprogrammed to support the activated and proliferating cell, but three additional clusters of EBV regulated genes adjust the infected immune cells to fine-tune cell signaling, migration, and immune response pathways, eventually. Our study reveals that more than 98 % of the 13,000 expressed genes in B-lymphocytes are regulated upon infection demonstrating that EBV governs the entire biology of its target cell.
Open AccessEpstein-Barr virus reprograms human B-lymphocytes immediately in the pre-latent phase of infection
Epstein-Barr virus (EBV) is a human tumor virus and a model of herpesviral latency. The virus efficiently infects resting human B-lymphocytes and induces their continuous proliferation in vitro, which mimics certain aspects of EBV’s oncogenic potential in vivo. This seminal finding was made 50 years ago, but how EBV activates primary human B-lymphocytes and how lymphoblastoid cell lines (LCLs) evolve from the EBV-infected lymphocytes is uncertain. We conducted a systematic time-resolved longitudinal study of cellular functions and transcriptional profiles of newly infected naïve primary B-lymphocytes. EBV reprograms these human cells comprehensively and globally. Rapid and extensive transcriptional changes occur within 24 hours of infection and precede any metabolic and phenotypic changes. Within the next 48 hours, the virus activates the cells, changes their phenotypes with respect to cell size, RNA and protein content and induces metabolic pathways to cope with the increased demand for energy, supporting an efficient cell cycle entry on day three post infection. The transcriptional program that EBV initiates consists of three waves of clearly discernable clusters of cellular genes that peak on day one, two, or three and regulate RNA synthesis, metabolic pathways and cell division, respectively. Upon the onset of cell doublings on day four the cellular transcriptome appears to be completely reprogrammed to support the activated and proliferating cell, but three additional clusters of EBV regulated genes adjust the infected immune cells to fine-tune cell signaling, migration, and immune response pathways, eventually. Our study reveals that more than 98 % of the 13,000 expressed genes in B-lymphocytes are regulated upon infection demonstrating that EBV governs the entire biology of its target cell.
- Open Access
- 2 March 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-11
Overexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma
Hepatoblastoma (HB) is the most common liver tumor of childhood and occurs predominantly within the first 3 years of life. In accordance to its early manifestation, HB has been described to display an extremely low mutation rate. As substitute, epigenetic modifiers seem to play an exceptional role in its tumorigenesis, which holds promise to develop targeted therapies and establish biomarkers for patient risk stratification. We examined the role of a newly described protein complex consisting of three epigenetic regulators, namely E3 ubiquitin-like containing PHD and RING finger domain 1 (UHRF1), ubiquitin-specific-processing protease 7 (USP7), and DNA methyltransferase 1 (DNMT1), in HB. We found the complex to be located on the promoter regions of the pivotal HB-associated tumor suppressor genes (TSGs) HHIP, IGFBP3, and SFRP1 in HB cells, thereby leading to strong repression through DNA methylation and histone modifications. Consequently, knockdown of UHRF1 led to DNA demethylation and loss of the repressive H3K9me2 histone mark at the TSG loci with their subsequent transcriptional reactivation. The observed growth impairment of HB cells upon UHRF1 knockdown could be attributed to reduced expression of genes involved in cell cycle progression, negative regulation of cell death, LIN28B signaling, and the adverse 16-gene signature, as revealed by global RNA sequencing. Clinically, overexpression of UHRF1 in primary tumor tissues was significantly associated with poor survival and the prognostic high-risk 16-gene signature. These findings suggest that UHRF1 is critical for aberrant TSG silencing and sustained growth signaling in HB and that UHRF1 overexpression levels might serve as a prognostic biomarker and potential molecular target for HB patients.
- 2 March 2018
- Published by Springer Nature in Clinical Epigenetics
- Vol. 10 (1) , 1-11
Open AccessOverexpression of UHRF1 promotes silencing of tumor suppressor genes and predicts outcome in hepatoblastoma
Hepatoblastoma (HB) is the most common liver tumor of childhood and occurs predominantly within the first 3 years of life. In accordance to its early manifestation, HB has been described to display an extremely low mutation rate. As substitute, epigenetic modifiers seem to play an exceptional role in its tumorigenesis, which holds promise to develop targeted therapies and establish biomarkers for patient risk stratification. We examined the role of a newly described protein complex consisting of three epigenetic regulators, namely E3 ubiquitin-like containing PHD and RING finger domain 1 (UHRF1), ubiquitin-specific-processing protease 7 (USP7), and DNA methyltransferase 1 (DNMT1), in HB. We found the complex to be located on the promoter regions of the pivotal HB-associated tumor suppressor genes (TSGs) HHIP, IGFBP3, and SFRP1 in HB cells, thereby leading to strong repression through DNA methylation and histone modifications. Consequently, knockdown of UHRF1 led to DNA demethylation and loss of the repressive H3K9me2 histone mark at the TSG loci with their subsequent transcriptional reactivation. The observed growth impairment of HB cells upon UHRF1 knockdown could be attributed to reduced expression of genes involved in cell cycle progression, negative regulation of cell death, LIN28B signaling, and the adverse 16-gene signature, as revealed by global RNA sequencing. Clinically, overexpression of UHRF1 in primary tumor tissues was significantly associated with poor survival and the prognostic high-risk 16-gene signature. These findings suggest that UHRF1 is critical for aberrant TSG silencing and sustained growth signaling in HB and that UHRF1 overexpression levels might serve as a prognostic biomarker and potential molecular target for HB patients.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Characteristics of aldosterone-producing adenomas: a tissue microarray study
Background: Sporadic aldosterone-producing adenomas (APA) are relevant cause of endocrine related hypertension in Primary Aldosteronism (PA). Next generation sequencing techniques have identified somatic mutations in APA harbored in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1 and PRKACA genes. Yet, a number of APA harbor no mutations in candidate genes (designated as wild type, WT) and little is known about genotype/phenotype correlation. Objectives: We investigated the tissue-based molecular and histopathological characteristics of 132 APAs after laparoscopic unilateral adrenalectomy in PA-patients and studied genotype/morphometry and histopathology correlation. Methods: Tumor-DNA was screened for somatic mutations in candidate genes by targeted (n=84) or whole-exome (n=48) sequencing. Accurate characterization of 179 morphometric parameters and of immunohistochemistry (IHC) results for steroidogenic enzymes CYP11B1, CYP11B2, CYP17, HSD3B1 and HSD3B2 was performed on tumor tissue microarrays from all samples by digital image analysis. Results: Prevalence of WT APA in our cohort was 34% and affected men more frequently. In 8/48 APA, non-recurrent somatic mutations (NR) were identified. H&E analysis demonstrated that 6 morphometric parameters correlated negatively with WT status whereas those same parameters correlated positively with the presence of KCNJ5 or NR (PWT and KCNJ5 mutated APA was found in 10 cytoplasmic parameters, including mainly color-based features (PKCNJ5 mutation status was negatively correlated with CYP11B1 and HSD3B1 expression (PWT, CACNA1D and NR APA significantly correlated positively with CYP11B1. ATP1A1 mutated APA correlated positively with CYP11B2 (PNR APA point towards a KCNJ5-like morphometric pattern associated with a WT-like steroidogenic enzymes expression pattern. WT APA presented an opposed morphometric pattern in comparison to mutated APA, indicating that in absence of detectable somatic mutations APA cells are driven towards a different cellular fate.
- 3 May 2017
- Published by Bioscientifica in Endocrine Abstracts
Characteristics of aldosterone-producing adenomas: a tissue microarray study
Background: Sporadic aldosterone-producing adenomas (APA) are relevant cause of endocrine related hypertension in Primary Aldosteronism (PA). Next generation sequencing techniques have identified somatic mutations in APA harbored in KCNJ5, ATP1A1, ATP2B3, CACNA1D, CTNNB1 and PRKACA genes. Yet, a number of APA harbor no mutations in candidate genes (designated as wild type, WT) and little is known about genotype/phenotype correlation. Objectives: We investigated the tissue-based molecular and histopathological characteristics of 132 APAs after laparoscopic unilateral adrenalectomy in PA-patients and studied genotype/morphometry and histopathology correlation. Methods: Tumor-DNA was screened for somatic mutations in candidate genes by targeted (n=84) or whole-exome (n=48) sequencing. Accurate characterization of 179 morphometric parameters and of immunohistochemistry (IHC) results for steroidogenic enzymes CYP11B1, CYP11B2, CYP17, HSD3B1 and HSD3B2 was performed on tumor tissue microarrays from all samples by digital image analysis. Results: Prevalence of WT APA in our cohort was 34% and affected men more frequently. In 8/48 APA, non-recurrent somatic mutations (NR) were identified. H&E analysis demonstrated that 6 morphometric parameters correlated negatively with WT status whereas those same parameters correlated positively with the presence of KCNJ5 or NR (PWT and KCNJ5 mutated APA was found in 10 cytoplasmic parameters, including mainly color-based features (PKCNJ5 mutation status was negatively correlated with CYP11B1 and HSD3B1 expression (PWT, CACNA1D and NR APA significantly correlated positively with CYP11B1. ATP1A1 mutated APA correlated positively with CYP11B2 (PNR APA point towards a KCNJ5-like morphometric pattern associated with a WT-like steroidogenic enzymes expression pattern. WT APA presented an opposed morphometric pattern in comparison to mutated APA, indicating that in absence of detectable somatic mutations APA cells are driven towards a different cellular fate.
- 8 August 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (9) , 3383-3388
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas
Autonomous thyroid adenomas (ATAs) are a frequent cause of hyperthyroidism. Mutations in the genes encoding the TSH receptor (TSHR) or the Gs protein α subunit (GNAS) are found in approximately 70% of ATAs. The involvement of other genes and the pathogenesis of the remaining cases are presently unknown. Here, we performed whole-exome sequencing in 19 ATAs that were paired with normal DNA samples and identified a recurrent hot-spot mutation (c.1712A>G; p.Gln571Arg) in the enhancer of zeste homolog 1 (EZH1) gene, which codes for a catalytic subunit of the polycomb complex. Targeted screening in an independent cohort confirmed that this mutation occurs with high frequency (27%) in ATAs. EZH1 mutations were strongly associated with known (TSHR, GNAS) or presumed (adenylate cyclase 9 [ADCY9]) alterations in cAMP pathway genes. Furthermore, functional studies revealed that the p.Gln571Arg EZH1 mutation caused increased histone H3 trimethylation and increased proliferation of thyroid cells. In summary, this study revealed that a hot-spot mutation in EZH1 is the second most frequent genetic alteration in ATAs. The association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells.
- 8 August 2016
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 126 (9) , 3383-3388
Recurrent EZH1 mutations are a second hit in autonomous thyroid adenomas
Autonomous thyroid adenomas (ATAs) are a frequent cause of hyperthyroidism. Mutations in the genes encoding the TSH receptor (TSHR) or the Gs protein α subunit (GNAS) are found in approximately 70% of ATAs. The involvement of other genes and the pathogenesis of the remaining cases are presently unknown. Here, we performed whole-exome sequencing in 19 ATAs that were paired with normal DNA samples and identified a recurrent hot-spot mutation (c.1712A>G; p.Gln571Arg) in the enhancer of zeste homolog 1 (EZH1) gene, which codes for a catalytic subunit of the polycomb complex. Targeted screening in an independent cohort confirmed that this mutation occurs with high frequency (27%) in ATAs. EZH1 mutations were strongly associated with known (TSHR, GNAS) or presumed (adenylate cyclase 9 [ADCY9]) alterations in cAMP pathway genes. Furthermore, functional studies revealed that the p.Gln571Arg EZH1 mutation caused increased histone H3 trimethylation and increased proliferation of thyroid cells. In summary, this study revealed that a hot-spot mutation in EZH1 is the second most frequent genetic alteration in ATAs. The association between EZH1 and TSHR mutations suggests a 2-hit model for the pathogenesis of these tumors, whereby constitutive activation of the cAMP pathway and EZH1 mutations cooperate to induce the hyperproliferation of thyroid cells.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
PRKACA somatic mutations are rare in aldosterone-producing adenomas.
Aldosterone-producing adenomas (APAs) are the most frequent cause of primary aldosteronism (PA). Somatic mutations of KCNJ5, ATP1A1, CACNA1D and ATP2B3 are involved in APAs formation while CTNNB1 and GNAS somatic mutations have been described in both APAs and in cortisol-producing adenomas (CPAs). In contrast, mutations of PRKACA coding for the catalytic subunit of protein kinase A have been yet only identified in CPAs. We investigated a consecutive series of APAs from 122 Conn-patients after unilateral adrenalectomy. We performed exome or bidirectional Sanger sequencing of tumor-tissue and evaluated mutations in candidate genes as well as PRKACA. Exome sequencing revealed PRKACA somatic mutations in two APAs (1.6%). One APA carried a L206R mutation, previously described only in cortisol-producing adenoma with overt Cushing’s syndrome, while in the second case a newly identified H88D mutation was found. Both affected patients were females with hypokalemic hypertension, aldosterone excess and lateralization during adrenal venous sampling. We functionally characterized the enzymatic activity of L206R and H88D mutated PKA catalytic subunit in vitro and characterized the immunoexpression of steroidogenic enzymes in affected tissues. Functional analysis showed that the newly found H88D mutation was not associated with gain of function of PKA. Interestingly, while CYP11B2 expression was found in the H88D-mutated APA, no co-expression of CYP11B1 was present. In contrast, in the L206R-mutated APA, CYP11B1 was expressed while CYP11B2 was weak or negative. Accordingly, biochemical Cushing’s syndrome was present only in the patient with the L206R mutation. Following adrenalectomy, both patients improved with a reduced number of antihypertensive medications and normalized potassium levels. We describe here for the first time PRKACA mutations in APAs as rare findings associated with PA. As cortisol co-secretion occurs in a sub-group of APAs other molecular mechanisms are likely to exist.
- 13 May 2016
- Published by Bioscientifica in Endocrine Abstracts
PRKACA somatic mutations are rare in aldosterone-producing adenomas.
Aldosterone-producing adenomas (APAs) are the most frequent cause of primary aldosteronism (PA). Somatic mutations of KCNJ5, ATP1A1, CACNA1D and ATP2B3 are involved in APAs formation while CTNNB1 and GNAS somatic mutations have been described in both APAs and in cortisol-producing adenomas (CPAs). In contrast, mutations of PRKACA coding for the catalytic subunit of protein kinase A have been yet only identified in CPAs. We investigated a consecutive series of APAs from 122 Conn-patients after unilateral adrenalectomy. We performed exome or bidirectional Sanger sequencing of tumor-tissue and evaluated mutations in candidate genes as well as PRKACA. Exome sequencing revealed PRKACA somatic mutations in two APAs (1.6%). One APA carried a L206R mutation, previously described only in cortisol-producing adenoma with overt Cushing’s syndrome, while in the second case a newly identified H88D mutation was found. Both affected patients were females with hypokalemic hypertension, aldosterone excess and lateralization during adrenal venous sampling. We functionally characterized the enzymatic activity of L206R and H88D mutated PKA catalytic subunit in vitro and characterized the immunoexpression of steroidogenic enzymes in affected tissues. Functional analysis showed that the newly found H88D mutation was not associated with gain of function of PKA. Interestingly, while CYP11B2 expression was found in the H88D-mutated APA, no co-expression of CYP11B1 was present. In contrast, in the L206R-mutated APA, CYP11B1 was expressed while CYP11B2 was weak or negative. Accordingly, biochemical Cushing’s syndrome was present only in the patient with the L206R mutation. Following adrenalectomy, both patients improved with a reduced number of antihypertensive medications and normalized potassium levels. We describe here for the first time PRKACA mutations in APAs as rare findings associated with PA. As cortisol co-secretion occurs in a sub-group of APAs other molecular mechanisms are likely to exist.
- 23 January 2016
- Published by Springer Nature in Mammalian Genome
- Vol. 27 (3-4) , 111-121
Exome sequencing identifies a nonsense mutation in Fam46a associated with bone abnormalities in a new mouse model for skeletal dysplasia
We performed exome sequencing for mutation discovery of an ENU (N-ethyl-N-nitrosourea)-derived mouse model characterized by significant elevated plasma alkaline phosphatase (ALP) activities in female and male mutant mice, originally named BAP014 (bone screen alkaline phosphatase #14). We identified a novel loss-of-function mutation within the Fam46a (family with sequence similarity 46, member A) gene (NM_001160378.1:c.469G>T, NP_001153850.1:p.Glu157*). Heterozygous mice of this mouse line (renamed Fam46a E157*Mhda) had significantly high ALP activities and apparently no other differences in morphology compared to wild-type mice. In contrast, homozygous Fam46a E157*Mhda mice showed severe morphological and skeletal abnormalities including short stature along with limb, rib, pelvis, and skull deformities with minimal trabecular bone and reduced cortical bone thickness in long bones. ALP activities of homozygous mutants were almost two-fold higher than in heterozygous mice. Fam46a is weakly expressed in most adult and embryonic tissues with a strong expression in mineralized tissues as calvaria and femur. The FAM46A protein is computationally predicted as a new member of the superfamily of nucleotidyltransferase fold proteins, but little is known about its function. Fam46a E157*Mhda mice are the first mouse model for a mutation within the Fam46a gene.
- 23 January 2016
- Published by Springer Nature in Mammalian Genome
- Vol. 27 (3-4) , 111-121
Exome sequencing identifies a nonsense mutation in Fam46a associated with bone abnormalities in a new mouse model for skeletal dysplasia
We performed exome sequencing for mutation discovery of an ENU (N-ethyl-N-nitrosourea)-derived mouse model characterized by significant elevated plasma alkaline phosphatase (ALP) activities in female and male mutant mice, originally named BAP014 (bone screen alkaline phosphatase #14). We identified a novel loss-of-function mutation within the Fam46a (family with sequence similarity 46, member A) gene (NM_001160378.1:c.469G>T, NP_001153850.1:p.Glu157*). Heterozygous mice of this mouse line (renamed Fam46a E157*Mhda) had significantly high ALP activities and apparently no other differences in morphology compared to wild-type mice. In contrast, homozygous Fam46a E157*Mhda mice showed severe morphological and skeletal abnormalities including short stature along with limb, rib, pelvis, and skull deformities with minimal trabecular bone and reduced cortical bone thickness in long bones. ALP activities of homozygous mutants were almost two-fold higher than in heterozygous mice. Fam46a is weakly expressed in most adult and embryonic tissues with a strong expression in mineralized tissues as calvaria and femur. The FAM46A protein is computationally predicted as a new member of the superfamily of nucleotidyltransferase fold proteins, but little is known about its function. Fam46a E157*Mhda mice are the first mouse model for a mutation within the Fam46a gene.